Company: RCUS
Filing Date: 2025-10-28
Form Type: 10-Q
Source: 0001724521-25-000116
Chunk: 196

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-28
Form: 10-Q
Item: Part I, Item 1
Chunk 196
---
ENSED CONSOLIDATED BALANCE SHEETS

(In millions, except per share amounts)

(unaudited)

September 30,2025December 31,2024ASSETS Current assets:Cash and cash equivalents$238 $150 Marketable securities593 828 Receivable from collaboration partners ($— and $6 from a related party)11 20 Prepaid expenses and other current assets15 18 Total current assets857 1,016  Long-term marketable securities10 14 Property and equipment, net42 47 Other noncurrent assets 65 73 Total assets$974 $1,150  LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:Accounts payable ($29 and $— to a related party)$42 $18 Deferred revenue ($52 and $85 to a related party)52 85 Other current liabilities141 123 Total current liabilities235 226  Deferred revenue, noncurrent ($53 and $234 to a related party)53 234 Long-term debt98 48 Other noncurrent liabilities152 157  Commitments Stockholders’ equity:Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 107.1 shares in 2025 and 92.2 shares in 2024 issued and outstanding1,815 1,617 Accumulated deficit(1,379)(1,132)Total stockholders’ equity436 485 Total liabilities and stockholders’ equity$974 $1,150 

See accompanying notes.

3

ARCUS BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(In millions)

(unaudited)

Number of shares of common stockCommon stock and additional paid-in capitalAccumulated deficit Accumulatedothercomprehensive income (loss) Totalstockholders’ equity Balance at December 31, 202375.5$1,311 $(849)$— $462 Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 13, Stockholders' equity)15.2228 — — 228 Issuance of common stock in connection with our equity award programs0.22 — — 2 Stock-based compensation—20 — — 20 Other comprehensive loss—— —